2 Dirt Cheap Healthcare Stocks to Buy in July

Healthcare has go Wall Street's bargain bin successful 2026, and worth hunters are starting to wage attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers person crushed multiples crossed Big Pharma, but the wreckage has created opportunities successful 2 cash-generative franchises trading astatine single-digit guardant net multiples. Heading into July, Novo Nordisk and Pfizer basal retired arsenic the cheapest large-cap names successful the group, with factual catalysts that could re-rate them earlier year-end.

Both study Q2 net successful aboriginal August, which means the model to presumption earlier the adjacent information constituent is narrow. Here's the lawsuit for each.

Novo Nordisk (NVO)

Novo Nordisk (NYSE:NVO) trades astir $49 aft a brutal 12-month derating that took the banal down 29% from a twelvemonth ago. The 52-week scope stretches from $35.12 to $71.80, and shares present beryllium good beneath the $47.32 statement expert target. Note for income investors: NVO is simply a Danish ADR, truthful dividends are taxable to overseas withholding taxation astatine the root earlier they deed your brokerage account.

The valuation is wherever this gets interesting. Novo trades astatine a trailing P/E of 12 and a guardant P/E of 14, with EV/EBITDA astatine 9. For a concern generating a 71% instrumentality connected equity and a 62% operating margin, that is simply a fire-sale multiple.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Novo Nordisk didn't marque the cut. Grab the names FREE today.

The bull lawsuit rests connected the Wegovy pill launch. CEO Mike Doustdar called it "the astir efficacious GLP-1 tablet present utilized by much than 1 cardinal patients since its January launch." Q1 FY2026 results, reported May 6, showed the oral mentation generating $2.26 cardinal successful its archetypal 4th and capturing 65% of caller US prescriptions successful the category. Obesity attraction grew 22% astatine changeless speech rates, and absorption raised 2026 guidance. Free currency travel output sits successful the precocious teens, and the committee funded a DKK 15 cardinal buyback done February 2027.

The risk: US pricing is the plaything factor. The Most-Favored-Nation model and planned ~50% Wegovy and ~35% Ozempic database terms cuts effectual January 2027 volition compress currency flow. CER income are inactive declining, and CagriSema missed its superior endpoint successful the REDEFINE 4 obesity trial. Q2 results onshore Aug. 5, with statement astatine 83 cents.